Zogenix, Inc.

335 articles about Zogenix, Inc.

• Zogenix, Inc., Astellas Pharma Inc. Enter Co-promotion Agreement

  8/3/2009

• Zogenix, Inc.'s Sumavel(TM) DosePro(TM) Approved by FDA for Acute Migraine and Cluster Headache: First Product Featuring Novel DosePro Needle-Free Delivery System

  7/16/2009

• Zogenix, Inc. Reports FDA Provides New PDUFA Date for Sumavel(TM) DosePro(TM) - Potential Final Approval July 2009

  2/18/2009

• Zogenix, Inc. Closes $18 Million Financing

  7/29/2008

• Zogenix, Inc. Announces Clinical Study Results for sumatriptan DosePro™, a Novel Migraine Treatment

  6/30/2008

• Zogenix, Inc. Completes Management Team with Cynthia Robinson, Ph.D., CDO, & Mark Thompson, VP, Sales & Managed Markets

  4/17/2008

• Zogenix, Inc. Files Registration Statement for Proposed Initial Public Offering

  3/24/2008

• Zogenix, Inc. Announces sumatriptan DosePro NDA Accepted for Filing by FDA

  3/20/2008

• Zogenix, Inc. Licenses European Development and Commercial Rights for Sumatriptan DosePro(TM) to Desitin Pharmaceuticals GmbH

  3/18/2008

• Zogenix, Inc. Raises $18 Million in Preferred Stock Financing

  1/9/2008

• Zogenix, Inc. Licenses Exclusive U.S. Commercial Rights for Late Stage, Controlled-Release, Opioid Product from Elan Corporation PLC

  11/28/2007

• Zogenix, Inc. Appoints David Nassif Executive Vice President and Chief Financial Officer

  6/7/2007

• Zogenix, Inc. Closes $10 Million Deal with GE Healthcare Financial Services

  3/19/2007

• Zogenix, Inc. Appoints J.D. Haldeman Vice President, Commercial Strategy & Corporate Communications

  10/16/2006

• Zogenix, Inc. Raises $60 Million, Buys Product

  8/28/2006